Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK | Zendy

H. Kurth | Zendy; Marty | Zendy; Roze | Zendy

Open Access

Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK

Author(s) -

H. Kurth,

Marty,

Roze

Publication year - 2012

Publication title -

medical devices evidence and research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.482

H-Index - 30

ISSN - 1179-1470

DOI - 10.2147/mder.s30913

Subject(s) - medicine , cohort , pegvisomant , somatostatin , acromegaly , demography , operations management , economics , growth hormone , sociology , hormone

Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. A simple decision-tree model aimed at comparing cost savings with ready-to-use Somatuline Autogel(®) (lanreotide) and Sandostatin LAR(®) (octreotide) for the UK, France, and Germany. The drivers of cost savings studied were the reduction of time to administer as well as a reduced baseline risk of clogging during product administration reported for Somatuline Autogel(®).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research